Provided by Tiger Trade Technology Pte. Ltd.

Nexalin Technology, Inc.

7.55
+3.2776.40%
Post-market: 7.18-0.3703-4.90%18:15 EDT
Volume:61.99M
Turnover:471.39M
Market Cap:6.26M
PE:-0.54
High:10.98
Open:8.80
Low:6.80
Close:4.28
52wk High:60.00
52wk Low:4.00
Shares:829.40K
Float Shares:611.90K
Volume Ratio:3,397.40
T/O Rate:10130.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.8684
EPS(LYR):-15.0475
ROE:-240.25%
ROA:-119.22%
PB:4.12
PE(LYR):-0.50

Loading ...

Nexalin wins US patent for dynamic frequency brain stimulation targeting anxiety, depression, insomnia

Reuters
·
Jun 04

Maxim Group Reaffirms Their Buy Rating on Nexalin Technology, Inc. (NXL)

TIPRANKS
·
May 21

Nexalin closes acquisition of PONM digital health platform for USD 1.3 million

Reuters
·
May 19

Nexalin Acquires AI-Integrated Digital Health Platform Behind Halo™ Clarity and Nexalin Neurocare™ Ahead of Planned FDA Pivotal Trial

THOMSON REUTERS
·
May 19

Nexalin Q1 FY26 net loss widens 5% to $2.1 million; revenue drops 64% to $14,950

Reuters
·
May 09

Nexalin Technology Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
May 08

Nexalin study shows insomnia improvement with 15 mA, 77.5 Hz brain stimulation

Reuters
·
Apr 28

Morgan Stanley Sticks to Their Buy Rating for Nuix Ltd. (NXL)

TIPRANKS
·
Apr 27

Nuix Ltd. (NXL) Gets a Buy from RBC Capital

TIPRANKS
·
Apr 24

BRIEF-Nexalin Technology Advances Clinical Trial Of HALO Clarity Toward Q2 2026 Enrollment

Reuters
·
Apr 22

Nexalin Technology enters agreements to advance HALO Clarity trial

TIPRANKS
·
Apr 22

Nexalin Technology Advances Pivotal Clinical Trial of Halo™ Clarity Toward Q2 2026 Enrollment

THOMSON REUTERS
·
Apr 22

Nexalin Technology: Patient Enrollment Currently Expected to Begin in Q2 of 2026

THOMSON REUTERS
·
Apr 22

Nexalin targets Q2 2026 enrollment for pivotal HALO Clarity insomnia trial

Reuters
·
Apr 22

BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems

Reuters
·
Apr 16

Nexalin targets Q2 FDA Q-Submission update for Alzheimer’s De Novo pathway

Reuters
·
Apr 15

Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China

THOMSON REUTERS
·
Apr 15

Nexalin Technology Inc: Plans to Submit an Amended FDA Q-Submission Application Based on Strategy Meetings in Q2 2026

THOMSON REUTERS
·
Apr 15

Nexalin to present at RedChip-hosted live investor webinar with Q&A session

Reuters
·
Apr 14

EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device

Benzinga_recent_news
·
Apr 09